PURPOSE: Doxazosin and terazosin are known to relax prostate smooth muscle through
blockade of α1-adrenergic innervation to the prostate. This action alone however does not …

Prostatic α1‐adrenoceptors are known to be involved in the pathophysiology of lower
urinary tract symptoms (LUTS) in patients with benign prostate obstruction (BPO). It is widely …

PURPOSE: Benign prostatic hyperplasia (BPH) causes mechanical urinary flow obstruction
by 2 components, namely an enlarged prostate (static component) and elevated smooth …

Previous studies documented the ability of quinazoline-based α1-adrenoceptor antagonists
to induce apoptosis in prostate cancer cells via an α1-adrenoceptor-independent …

PURPOSE:: Cyclooxygenase-2 (COX-2) is expressed in human BPH tissue and displays
either a pro-inflammatory effect or a proliferative effect on prostate cells. The aim of this study …

Benign prostatic hyperplasia (BPH) is a chronic condition common in older men that can
result in bothersome lower urinary tract symptoms. The molecular mechanisms and …

Abstract α 1-Adrenoceptor antagonists, have been documented to induce apoptosis and
reduce prostate tumor vascularity in benign and malignant prostate cells. The quinazoline …

This study examined whether various species of Epilobium, a phytotherapeutic agent used
in folk medicine as a treatment for benign prostatic hyperplasia, may have an …

All forms of androgen-deprivation therapy, including finasteride, induce distinctive histologic
changes in benign and neoplastic prostatic epithelial cells, including cytoplasmic clearing …

PURPOSE: The Prostate Cancer Prevention Trial (PCPT) showed that the 5α-reductase
inhibitor (5ARI) finasteride significantly decreased the 7-year period prevalence of prostate …